Engflag

Cotrip

Quick links to important sections

Cotrip

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cotrip

What is Cotrip?

Cotrip is a pharmaceutical formulation that combines two distinct active ingredients: amitriptyline and chlordiazepoxide. This combination is designed to address complex clinical presentations where symptoms of depression and anxiety occur simultaneously.

Therapeutic Components

The efficacy of this medication is derived from the synergistic action of its two primary components:

  • Amitriptyline: This is a tricyclic antidepressant. It works by influencing the balance of certain natural chemicals, known as neurotransmitters, in the brain. Specifically, it inhibits the reuptake of serotonin and norepinephrine, which helps to elevate mood and alleviate depressive symptoms.
  • Chlordiazepoxide: This belongs to the benzodiazepine class of medications. It acts as an anxiolytic by enhancing the effect of gamma-aminobutyric acid (GABA), a neurotransmitter that promotes calmness and reduces excessive brain activity associated with tension and nervousness.

Common Uses

This medication is typically utilized in the management of moderate to severe manifestations of anxiety and depression. By addressing both emotional states at once, it aims to provide a comprehensive approach to stabilizing mood and reducing physical or mental symptoms of distress.

Mechanism of Action

Unlike medications that target a single symptom, Cotrip provides a dual-action mechanism. While the amitriptyline component works toward long-term mood stabilization, the chlordiazepoxide component helps manage more immediate feelings of apprehension or agitation. This integrated approach is often considered when single-agent therapies have not achieved the desired therapeutic goals.

Regulatory References

  1. Tricyclic Antidepressants (TCAs) Overview
  2. Amitriptyline Public Assessment Report (NL MEB)
  3. NIH/NCBI Bookshelf on Amitriptyline Mechanism
  4. NIH Review on TCAs Mechanism

What side effects are possible with Cotrip?

Cotrip, a combination of trimethoprim and sulfamethoxazole, is associated with a range of possible side effects documented in governmental regulatory sources, ranging from common to very rare but serious adverse reactions.

Adverse Reaction Categories

The most commonly reported adverse effects involve the gastrointestinal system, such as nausea and diarrhea, and the nervous system, typically headache. Skin rash is also a common occurrence. A particularly frequent metabolic side effect is hyperkalaemia (high blood potassium).

Serious and Clinically Significant Risks

Serious adverse reactions, though rare, are critical and may be fatal. These include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), often appearing in the first weeks of treatment. Other very rare but life-threatening reactions are fulminant hepatic necrosis, severe blood dyscrasias (e.g., agranulocytosis, aplastic anaemia), Acute Respiratory Distress Syndrome (ARDS), and circulatory shock.

Regulatory documents emphasize that the risk of serious adverse effects may be higher with high-dose regimens or prolonged use.

Safety Restrictions and Monitoring

Cotrip is contraindicated in patients with documented megaloblastic anaemia due to folate deficiency, severe hepatic or renal insufficiency (if unmonitored), a history of drug-induced immune thrombocytopenia, and in infants under two months of age. It is also contraindicated in pregnant women at term and nursing mothers.

During treatment, especially with high doses or long courses, regular laboratory monitoring of blood counts, serum potassium, and renal function is advised. The medicine must be discontinued immediately at the first sign of a severe reaction, such as a rash, persistent fever, or new pulmonary symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cotrip (Amitriptyline) is a serious, potentially life-threatening event that requires immediate medical attention. Regulatory documents specify that signs of overdosage can manifest across multiple systems, often involving severe Central Nervous System (CNS) and cardiovascular toxicity.

Documented Overdose Manifestations

System Severe Symptoms Listed in Labeling
Cardiovascular Ventricular arrhythmias, prolonged QRS interval, severe hypotension, cardiac arrest
CNS / Anticholinergic Coma, seizures, hyperpyrexia, agitation, confusion, urinary retention

Cardiac arrhythmias and CNS complications pose the greatest threat and can occur suddenly, even if initial symptoms appear mild. Therefore, regulators mandate that any suspected overdose requires hospitalization and continuous cardiac monitoring. There is no specific antidote known for Amitriptyline overdose. Management is strictly symptomatic and supportive, which includes procedures like activated charcoal administration and the use of sodium bicarbonate to address specific cardiac toxicity or acidosis. Children and elderly patients are noted as populations requiring particular surveillance due to increased risk of toxicity.

Therapeutic Uses of Cotrip

What Cotrip Treats: Main Uses and Benefits

Cotrip (Amitriptyline) is a relevant therapy commonly used to provide symptomatic relief and stabilization across two primary therapeutic domains: chronic pain and mood disorders. It is a recognized option for addressing both persistent discomfort and severe emotional symptoms.

Symptom Relief and Therapeutic Contexts

This medication is commonly used to help manage symptoms across several conditions, including Major Depressive Disorder (MDD), certain forms of neuropathic pain (such as diabetic or post-herpetic neuralgia), chronic tension-type headaches, and migraine prophylaxis. It is also applied in specific pediatric cases to address nocturnal enuresis (bedwetting). The therapy is generally employed in chronic, treatment-resistant, or recurrent scenarios where symptoms like burning nerve pain, persistent low mood, or severe sleep disturbances create noticeable functional strain.

“The supportive relief provided assists with maintaining functional stability when symptoms are more noticeable.”

The core benefit is reducing the overall burden of distressing manifestations and assisting patients in coping more steadily with symptom fluctuations, thereby contributing to general well-being.

Quick Fact: Relief for Chronic Nerve Pain

Eligibility and Restrictions for Use

Eligibility for Cotrip (Amitriptyline)

Official regulatory documents define strict criteria for who can and cannot use Cotrip (Amitriptyline). The medicine is primarily approved for adults (18+ years) for general use. Use is contraindicated in several populations due to significant risk.

Classification Population/Condition
Contraindicated Patients in the acute recovery phase following a myocardial infarction, individuals with severe liver disease, those with pre-existing heart block or cardiac rhythm disorders, or those taking Monoamine Oxidase Inhibitors (MAOIs). Use is also contraindicated in children under 6 years of age.
Not Recommended Children and adolescents under 18 years for general indications (e.g., depression, pain), as safety and efficacy are not established.
Conditional Use Older adults (65+ years) require caution. Use is restricted to a lower starting dose due to increased sensitivity. Patients with a history of angle-closure glaucoma, urinary retention, or convulsive disorders require close monitoring.
Age Restriction Children aged 6 years and above are eligible only for the specific condition of nocturnal enuresis.

Pregnancy and Lactation Status: The FDA classifies Amitriptyline as Pregnancy Category C. Use during pregnancy is conditional on whether the potential benefit justifies the potential risk. Due to excretion into breast milk, discontinuation of the drug or nursing is recommended.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information identifies specific drug classes and medicinal products that interact with Cotrip (Sulfamethoxazole/Trimethoprim), requiring precautions or avoidance.

Interacting Drug Categories:

  • Anticoagulants (e.g., Warfarin): Concomitant use increases the effect of the anticoagulant, necessitating careful monitoring of the International Normalized Ratio (INR).
  • Oral Hypoglycemics (e.g., Sulfonylureas): Co-administration may enhance the blood sugar-lowering effect, potentially leading to hypoglycemia.
  • Potassium-Elevating Agents: The Trimethoprim component can elevate serum potassium; concurrent use with Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), or potassium-sparing diuretics may cause dangerously high potassium levels, especially in the elderly.
  • Antifolate Agents (e.g., Methotrexate, Pyrimethamine): The combination increases the risk of bone marrow suppression and other toxicities due to an additive antifolate effect.

Mandatory Restrictions and Monitoring:

  • Dofetilide (an antiarrhythmic) is contraindicated for use with Cotrip due to the potential for significantly increased Dofetilide concentration, posing a major risk to heart rhythm.
  • Phenytoin and Digoxin levels may increase when taken with Cotrip, requiring therapeutic drug monitoring for dose adjustment.
  • Co-administration with Diuretics (specifically Thiazides) in older adult populations may increase the risk of low platelet count (thrombocytopenia).

The interaction profile primarily involves pharmacokinetic mechanisms, where Cotrip inhibits the metabolism or renal excretion of other drugs, resulting in elevated systemic exposure. This includes specific drugs that require mandatory avoidance, such as Dofetilide, and numerous others that necessitate intensive clinical and laboratory monitoring.

Mechanism of Action

Modulating Serotonin and Norepinephrine Signaling

Cotrip's primary mechanism involves acting as an inhibitor on two key membrane transport proteins: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). By binding to these transporters, the drug blocks the reuptake of the chemical messengers serotonin and norepinephrine from the synaptic cleft back into the presynaptic neuron

. This action increases the concentration and duration of signaling of these monoamines, which modulates central nervous system pathways that influence the body's physiological state.

Non-Selective Receptor Blockade

In addition to reuptake inhibition, Cotrip acts as an antagonist (blocker) on several non-monoaminergic receptor systems. These include the Histamine H1 receptors and various Muscarinic Cholinergic receptors. These secondary interactions alter regulatory pathways in both the central and peripheral nervous systems, leading to physiological effects, including changes in arousal and altered regulation of involuntary body functions such as glandular secretion and smooth muscle tone.

Dosage and Administration Information

The administration of Cotrip (Amitriptyline) follows established procedures for route, dosage, and scheduling. The primary method of intake is oral administration using film-coated tablets or an oral solution. For certain intensive treatments, the medicine is also utilized for temporary intramuscular (IM) or intravenous (IV) injection in a controlled clinical setting.

Standard Regimens and Timing

For adult outpatient use, the total daily dose typically ranges from 50 mg to 150 mg, which is often administered as a single dose at bedtime to align with product characteristics. Conversely, the required daily dosage for indications like chronic pain management is generally lower, falling between 25 mg and 75 mg. The medicine may be taken with or without food. Tablets are generally instructed to be swallowed whole with water.

Dose Adjustment and Duration

Treatment typically begins with a low starting dose and progresses through a process of gradual titration, where the amount is slowly increased over several days or weeks until the maintenance level is achieved. For conditions such as depression, maintenance therapy is often continued for a minimum of three months to sustain the benefit, and discontinuation involves a gradual reduction (tapering) of the dose.

Population-Specific Rules

Clinical guidelines suggest dose adjustments for certain groups. Older adults, for instance, are often started on a lower regimen, such as 10 mg to 25 mg daily, due to increased sensitivity. Specific pediatric doses (e.g., 10 mg to 50 mg) are used for nocturnal enuresis, administered shortly before sleep.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

Research has investigated the use of Drug X for pain in patients with Condition A. The body of research includes both randomized controlled trials (RCTs) and long-term observational studies.

  • One key study evaluated whether combining Drug X with standard care influenced long-term outcomes and examined the frequency of flare-ups. This study explored the onset of action with this combination.
  • The delivery method was studied to assess the duration of symptom effects over a 24-hour period.
  • Head-to-head trials against older treatments were conducted to compare outcomes across different patient groups.

Safety and Tolerability Profile

Research evaluated the tolerability profile of Drug X across diverse patient populations.

  • The studies examined specific dose ranges, with researchers monitoring for adverse events.
  • Adverse events reported included nausea and fatigue.
  • Individuals with kidney issues were generally excluded from trials, or specific adverse events were observed in this subset; further study is needed to assess the risk in this population.

Further research is needed to further assess the findings in individuals with severe, acute symptoms. It is not yet clear whether the findings apply equally to all age groups or specific co-morbidities.

Key Studies & References

  1. Randomized, Controlled Trial Comparing Drug X to Standard of Care for Condition A
  2. Guideline for the Management of Condition A in Patients with Renal Impairment

Frequently Asked Questions (FAQ)

Common questions about Cotrip (FAQ)

Q: How quickly does Cotrip start to work?

A: The therapeutic effect from Cotrip is generally observed after 2 to 4 weeks of starting treatment. Official information indicates this medicine is not immediate-acting, and its effects are designed to build up over this time period.

Q: How long do the effects of a dose of Cotrip typically last?

A: Cotrip is often prescribed as a single dose at bedtime, which is based on its drug characteristics that support a once-daily regimen. This dosing is consistent with the drug's characteristics for a once-daily regimen.

Q: Why do official sources say you cannot stop taking Cotrip suddenly?

A: Official instructions state that the drug should be withdrawn gradually over several weeks. This gradual reduction is described as a way to avoid potential withdrawal symptoms that can happen if the medicine is stopped abruptly.

Q: What over-the-counter (OTC) painkillers or cold medicines interact with Cotrip?

A: Official warnings indicate that Cotrip can enhance the sedative effects of other medicines that act on the central nervous system (CNS). This includes certain cold medicines and some narcotic pain relievers, which is described as a potential risk of extreme drowsiness.

Q: What happens if Cotrip is taken with alcohol?

A: Regulatory guidance states that the co-use of alcohol with this medicine should be avoided. Cotrip may enhance the response to alcohol and significantly increase the sedative (drowsiness) effects of both substances.

Q: What happens if I have an allergic reaction to Cotrip?

A: Cotrip is associated with a risk of severe adverse reactions, such as severe allergic responses. Official documents state that discontinuation of treatment is required immediately at the first sign of a severe reaction, such as a spreading rash or persistent fever.

Q: Is Cotrip safe for people with kidney problems?

A: Regulatory documents indicate that patients with reduced renal function (kidney issues) generally do not require a mandatory dosage adjustment. Official dosing guidelines describe that these patients typically receive the usual regimen.

Q: Is there a generic version of Cotrip available?

A: As a medicine whose generic name is Amitriptyline, generic forms of the medicine are authorized and available from various manufacturers. These generic medications are reviewed and overseen by regulatory bodies.

Q: Is it common to feel dizzy or tired when starting Cotrip?

A: Official product information lists dizziness and somnolence (tiredness or drowsiness) as some of the commonly encountered side effects of the medicine.

Q: Does Cotrip cause weight gain or weight loss?

A: Regulatory and research data indicate that weight gain has been described in official sources as a common side effect associated with the long-term use of the drug.

Q: Will Cotrip make it difficult to drive or operate machinery?

A: Due to its sedative effects, the drug may impair the mental and/or physical abilities required to perform hazardous tasks. For this reason, official warnings describe the potential for impairment when operating machinery or driving a motor vehicle.

Q: Can I take vitamins or herbal supplements while using Cotrip?

A: Regulatory guidance states that the herbal remedy St. John's wort should be avoided while taking this medicine. There is insufficient regulatory data to determine if other vitamins, complementary medicines, or herbal remedies carry a risk of interaction.

Q: Is Cotrip considered a controlled substance?

A: Cotrip (Amitriptyline) is not considered a controlled substance by regulatory bodies. It is not classified as carrying a high risk of addiction or misuse, distinguishing it from controlled pain or sedative medications.

Q: Why is Cotrip only available by prescription?

A: The drug is classified as prescription-only because of its characteristics, which include a complex interaction profile and a need for necessary monitoring for serious adverse reactions.

Q: How is the safety of Cotrip monitored after it is approved?

A: Regulatory authorities conduct continuous post-market surveillance of the medicine. This involves collecting and evaluating patient experience after the drug is released to ensure its continued safety and identify the need for any risk management actions.

Q: Does Cotrip affect the effectiveness of birth control?

A: Official information indicates that the concentration of Cotrip in the body may be increased in women taking oral contraceptives. However, the clinical significance of this interaction—whether it affects the effectiveness of the birth control itself—is generally unknown.

Q: Is the effectiveness of Cotrip affected by diet?

A: The official patient information leaflet states that the medicine can be taken with or without food. The drug's effectiveness is generally not influenced by whether it is taken alongside a meal.

Q: Is the Cotrip tablet scored for splitting?

A: Cotrip film-coated tablets may include a score line. However, regulatory documents clarify that this line is often present only to facilitate breaking for ease of swallowing, and the score line is not an indication that the tablet can be accurately split for dosing purposes.

Q: Can I use a daily pill box with Cotrip?

A: Official storage requirements state that the medicine should be kept in its original container. The original container provides necessary protection from light and moisture to maintain product stability.

Q: What is the typical duration of treatment with Cotrip?

A: For indications like depression, treatment is typically continued for up to 6 months after recovery as part of a standard regimen. For other conditions, such as chronic nerve discomfort, therapy may be required for several years, which requires professional oversight.

Q: Was Cotrip tested on children or teenagers in clinical trials?

A: Specific doses are approved for children aged 6 years and above for the condition of nocturnal enuresis. However, the drug is not recommended for general use in children and adolescents under 18 years because safety and efficacy are not fully established for those broader indications.

Q: Is Cotrip associated with any adverse mental health or mood changes?

A: Regulatory documents include a warning regarding an increased risk of suicidal ideation and behavior in adolescents and young adults. The drug is also associated with psychiatric adverse effects such as excitement, agitation, restlessness, and the rare potential to induce mania.

Q: Does Cotrip affect fertility in men or women?

A: Regulatory information indicates there is no evidence that the use of Cotrip affects fertility in either men or women.

How should Cotrip be stored and disposed of?

How to Store and Dispose of Cotrip (Amitriptyline)

The storage and disposal of Cotrip (Amitriptyline) must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirements

Item Requirement
Temperature Store tablets at Controlled Room Temperature (typically 20 C to 25 C). The oral solution must not be stored above 25 C and not be refrigerated or frozen.
Protection Keep the medicine in its original container, tightly closed, and protect from heat, moisture, and light.
Stability The oral solution must be discarded 30 days after first opening the container.
Safety Keep out of the sight and reach of children.

Disposal

Ask a pharmacist or healthcare professional how to properly dispose of any unused or expired product. Do not dispose of medicine via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cotrip found in:

A-Z Index: